Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Expands By 13.0%

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 20,000 shares, an increase of 13.0% from the October 15th total of 17,700 shares. Based on an average trading volume of 4,700 shares, the short-interest ratio is currently 4.3 days.

Jasper Therapeutics Price Performance

Shares of JSPRW stock traded up $0.00 during trading hours on Monday, reaching $0.19. 4,084 shares of the company were exchanged, compared to its average volume of 17,280. The stock’s fifty day moving average is $0.21 and its two-hundred day moving average is $0.21. Jasper Therapeutics has a fifty-two week low of $0.04 and a fifty-two week high of $0.38.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.